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 Neoplastic epithelia may remain dormant and clinically unapparent in human patients for decades. Multiple 
risk factors including mutations in tumor cells or the stromal cells may affect the switch from dormancy to ma-
lignancy. Gene mutations, including p53 mutations, within the stroma of tumors are associated with a worse 
clinical prognosis; however, it is not known if these stromal mutations can promote tumors in genetically at-risk 
tissue. To address this question,  Apc  Min/+  and  Apc  Min/+Rag2−/−  mice, which have a predilection to mammary car-
cinoma (as well as wild-type (wt) mice), received mesenchymal stem cells (MSC) with mutant p53 (p53MSC) 
transferred via tail vein injection. In the wt mouse, p53MSC circulated in the periphery and homed to the mar-
row cavity where they could be recovered up to a year later without apparent effect on the health of the mouse. 
No mammary tumors were found. However, in mice carrying the  Apc  Min/+  mutation, p53MSC homed to mam-
mary tissue and signifi cantly increased the incidence of mammary carcinoma. Tumor necrosis factor (TNF)-
α-dependent factors elaborated from mesenchymal cells converted quiescent epithelia into clinically apparent 
disease. The increased cancer phenotype was completely preventable with neutralization of TNF-α or by transfer 
of CD4 + regulatory T cells from immune competent donors, demonstrating that immune competency to regulate 
infl ammation was suffi cient to maintain neoplastic dormancy even in the presence of oncogenic epithelial and 
stromal mutations. The signifi cant synergy between host immunity and mesenchymal cells identifi ed here may 
restructure treatments to restore an anticancer microenvironment. 
 Introduction 
 By midlife, the majority of people have microscopic foci of malignant cells throughout their body, yet the inci-
dence of clinically apparent tumors is strikingly lower [ 1 ]. 
Autopsy studies reveal a profound discrepancy between the 
presence of subclinical malignancy and clinically apparent 
cancer [ 2–4 ]. Multiple factors may affect this switch from 
dormant to overt disease, including additional gene muta-
tions within tumor cells, changes in the systemic immune 
response, and/or alterations in the microenvironment and 
stromal cells proximate to the cancer cells. 
 Bone marrow-derived cells (BMDC) invade and re-
side within infl ammed tissues. Within these tissues, cells 
derived from the marrow can differentiate as myofi broblasts 
and fi broblasts and contribute substantially to the signaling 
environment surrounding regenerating tissue [ 5 ], and they 
are instrumental in directing epithelial cell regeneration 
and wound repair. Within established tumors, BMDC are 
recruited as cancer-associated fi broblasts (CAF), which have 
a phenotype similar to that of activated fi broblasts thus 
sharing a “wound-healing” repertoire of chemokine and 
cytokine [ 6 ] production. Mesenchymal stem cells (MSC), 
which can be found in the marrow, also localize to areas 
of established carcinoma and infi ltrate into the tumor as 
tumor stroma [ 7 ]. MSC promote breast cancer metastasis 
through effects on local tumor growth and migration, and 
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School under IACUC approval. Female C57BL/6 Apc  Min/+  
(B6Min),  Apc  Min/+  Rag2  −/−  (B6RagMin), and  wt (B6) littermates 
were genotyped prior to experiments, and at euthanasia. 
Experiments were conducted using separate trials with 
5–10 mice each and results combined for statistical anal-
yses. C57BL/6 Apc  Min/+  mice are at risk for mammary tumors 
and 1% of female mice develop tumors by 26 weeks of age. 
 Apc  Min/+  Rag2  −/−  mice are at a higher risk of mammary carci-
noma and 10% of female mice develop mammary tumors by 
26 weeks of age. 
 Wild-type bone marrow transplantation 
and MSC infusion 
 Bone marrow transplantation was performed as previ-
ously described [ 12 ] using enhanced green fl uorescent 
protein (eGFP)-labeled total bone marrow from C57BL/6J-
 β-actin-EGFP mice (Jackson laboratories, Bar Harbor, ME) 
or eGFP-MSC plus 3–5 million unmarked support marrow 
cells transplanted into irradiated (900 rads) recipients via 
tail vein injection. Recipient mice were 6–8 weeks of age. 
Donor mice were 8–12 weeks of age. Freshly cultured cells 
were used at fi rst passage. Cultured wtMSC or p53MSC 
were age-matched for experiments and used at Passages 
12–15. 
 Isolation, culture, and infusion of p53MSC 
and wtMSC 
 Wild-type bone marrow was isolated and cultured as 
previously described [ 13 ]. p53wt (wt) and MSC with a CAF 
phenotype and carrying p53 mutation (p53MSC) were iden-
tifi ed, characterized, and transfected with a monomeric 
DS-red containing plasmid as described in Supplemental 
Methods. 
 Immunomodulation 
 T REG transfer and neutralization of TNF-α by anti-TNF-α 
antibody is described in Supplemental Methods. 
 Primary tumor, tumor transplantation, and histological 
evaluation of tissues 
 p53MSC-induced B6Min mammary tumors were excised. 
One half was processed for histology and Ki-67 expression, 
and ½ was minced, digested, and cell suspensions injected 
into the mammary fat pad of recipient female B6Min mice. 
All mammary tissue and tumors were evaluated for his-
tology and epithelial cell proliferation as described in 
Supplemental Methods. For ex vivo proliferation studies, 
cells were placed in tissue culture with Dulbecco’s modifi ed 
Eagle’s medium (DMEM) 10% fetal calf serum (FCS) and 
grown as a monolayer. 
 Migration by monolayer wound-healing assay 
 MCF-7 cells were grown to 90% confl uence and the 
cell monolayer was then wounded by a plastic tip (1 mm). 
Monolayers were washed, photographed, and media 
replaced with control medium or p53MSC-conditioned me-
dium ± chemokines and healing measured as described in 
Supplemental Methods. 
via priming of distant sites to become conducive docking 
sites for tumor cells [ 7 ]. 
 Cancer-associated fi broblasts have been shown to carry 
genetic and epigenetic mutations, which are thought to 
impact their clinical behavior [ 8–10 ]. Recently, it has been 
suggested that CAF may play as much a role in cancer for-
mation as do the epithelial-derived tumor cells themselves. 
Mutations in stromal p53 have been demonstrated in CAF 
associated with multiple tumor types. Mammary tumors 
containing p53-defi cient stromal fi broblasts developed 
faster and are more aggressive than tumors containing 
wild-type (wt) stromal fi broblasts [ 11 ]. Though it is clear 
that stromal cells have dramatic impact on established 
tumors, it is less clear what effect these cells have on the 
earliest stages of malignancy or what role, if any, they may 
have in converting microscopic malignant foci within at-
risk tissue to frank malignant disease. Interestingly, it has 
been suggested that mammary stroma may be a critical 
target for chemical-induced transformation. Studies using 
NMU as a transforming agent demonstrate that the mam-
mary stroma can be a direct target of chemical transfor-
mation and precedes the transformation of rat mammary 
epithelial cells in a rat model of chemical-induced mam-
mary carcinoma [ 8 ]. 
 Here we show that mutant p53MSC home to mammary 
tissue under the infl uence of dysregulated infl ammation. 
Once within at-risk tissue, p53MSC accelerated neoplastic 
cell growth. Homing and proliferation of p53MSC within 
the mammary epithelium resulted in a dramatic increase 
in disease incidence and tumor size, and a decrease in 
the time to clinically apparent disease in mice at-risk for 
mammary carcinoma. The p53MSC themselves did not 
promote mammary tumors in wt mice that were not at 
risk for the disease. Further, the increased cancer pheno-
type was dependent upon tumor necrosis factor (TNF)-α, 
and accelerated tumor formation was completely reversed 
with neutralization of TNF-α via neutralizing antibody or 
by transfer of competent T-regulatory cells (T REG ). Altered 
MSC signaling converted quiescent in situ carcinoma to 
clinically apparent disease in a tissue-specifi c fashion. 
The signifi cant contribution of immune dysregulation to 
procancer MSC activity provides additional mechanisms 
for the clinical stratifi cation of breast cancer and may re-
structure treatment targets toward restoring an anticancer 
microenvironment. 
 Materials and Methods 
 Please see Supplemental Methods for additional details. 
 Human tissue 
 Human breast cancer and normal breast tissue sam-
ples from de-identifi ed individuals were obtained from 
the UMass Cancer Center Tissue and Tumor Bank http://
www.umassmed.edu/cancercenter/tissuebank/index.aspx) 
with IRB approval and evaluated for p53 expression (see 
Supplemental Methods). 
 Experimental animals 
 Animal work was performed at Massachusetts Institute 
of Technology or at the University of Massachusetts Medical 
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non-neoplastic mammary glands and associated connective 
tissue for p53 and α-SMA expression. Small glands were 
devoid of α-SMA expression. Myoepithelial cells along lob-
ular ductules stain strongly positive for α-SMA. Fibroblasts 
within the stroma were devoid of α-SMA signal. We did not 
detect any p53 staining within any cell of benign mammary 
tissue ( Fig. 1H and  1I ). These fi ndings confi rm the published 
observation of rare (1%–5%) p53 + CAF cells within breast 
cancer stroma [ 11 , 15 , 17–19 ]. 
 Wild-type MSC are not associated with an increase 
risk of mammary carcinoma 
 We hypothesized that p53 mutations in stromal cells 
could drive the transition of occult malignant cells to frank 
mammary carcinoma in at-risk tissue. As a fi rst step in eval-
uating the p53MSC promotion of mammary carcinoma, we 
characterized the in vivo activity of wtMSC in wtC57BL/6 
mice (B6) not prone to mammary carcinoma compared 
with wtMSC given to C57BL/6 Apc Min/+  (B6Min) mice that 
have a low but signifi cant spontaneous rate of developing 
mammary carcinoma, and found that wtMSC did not con-
tribute to a malignant phenotype in either mouse model (see 
 Supplemental Table 1 ; Supplementary materials are avail-
able online at http://www.liebertonline.com/scd). 
 Infused p53MSC-CAF are not associated 
with mammary carcinoma in B6 mice 
 We next investigated the fate of MSC hemizygous for p53 
307 Thr–Ile mutation [ 13 ] (p53MSC) (which coincides with 
position 312 in the DNA-binding region of human p53, a 
mutation found in human cancers [ 20 ]) in the B6 mice. This 
 Statistical analyses 
 Mammary tumor incidence was compared using Fisher 
exact  t -test. Ki-67 index and assessment of stroma was com-
pared between groups using 2-tailed  t -test. In vitro data 
were compared using Student’s  t -test using a minimum of 3 
replicates per experimental point, and experiments repeated 
2–3 times for reproducibility. 
 Results 
 Cancer-associated fi broblasts from human breast 
cancer contain a population of p53-mutated 
stromal cells 
 Stromal cells with p53 mutations have been identifi ed as-
sociated with breast [ 14,15 ], prostate [ 16 ], and other epithelial 
cancer cells and are predictive of aggressive tumor behavior 
and metastasis. While there is controversy with regard to 
the specifi c mutation and frequency of stromal p53 muta-
tions in human breast cancer specimens [ 15 , 17–19 ], there 
is a growing literature that demonstrates a role for nonau-
tonomous p53 effects between stroma and mammary epi-
thelial cells [ 11 ]. We fi rst assessed p53 expression in human 
breast cancer stroma. Specifi c p53 immunohistochemistry 
(IHC) of 15 consecutive breast cancer specimens archived 
by the UMass tumor bank was done and our data support 
the notion that overexpression of p53, which can be asso-
ciated with clinically relevant mutations, occurs commonly 
within a population of CAF ( Table 1 ). p53 + stromal cells were 
found in 67% of breast cancer specimens ( Fig. 1A–1C ) and 
expressed α-smooth muscle actin (α-SMA) indicative of an 
activated fi broblast phenotype ( Fig. 1D–1G ). p53 + cells were 
found as isolated cells within activated stroma. We evaluated 
 T able 1.  H uman B reast C ancer —C linical I nformation 
Sample number Age Cancer type Grade pT pN pM ER/PR/Her2
p53
Epithelial Stromal
1 65 Ductal 2 1 b 0 − +/−/− − +
2 83 Ductal 2 1 b 0 − +/+/− − +
3 66 Ductal 2 1 b 3 a − +/−/− − −
4 69 Ductal/lobular 2 2 0 − +/+/− − −
5 59 Ductal 3 2 0 − +/−/− + +
6 79 Ductal 2 1 c 0 − +/+/− − +
7 72 Ductal 2 1 b 0 − +/+/− + +
8 61 Ductal 2 1 b 0 − +/+/− − +
9 44 Ductal 2 2 0 − +/+/− + +
10 61 Ductal 2 1 b 0 − +/+/− − +
11 82 Ductal 2 4 1 b − +/+/− − +
12 73 Ductal 2 1 c 0 − +/+/− − −
13 45 Ductal 1 1 b 1mi − +/+/− − −
14 47 Ductal 3 1 b 0 − +/−/− + +
15 59 Ductal 3 1 c 0 − −/−/+ + −
 Grade: 1, well-differentiated; 2, moderately differentiated; and 3, poorly differentiated. 
 pT: tumor size and extent. 
 pN nodes:  a ≤ 0.2 cm;  b ≥ 0.2 cm; mi, micrometastasis <0.2 cm. 
 pM metastasis: +/−. 
 ER/PR/Her2: estrogen receptor, progesterone receptor, and Her2 status of tumor sample. 
 p53 status for epithelium and stroma: Negative (−) if there is no staining, (+) if any cell in the appropriate 
compartment stains for nuclear p53. 
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were verifi ed by fl uorescence-activated cell sorting (FACS) 
to lack hematopoietic stem cell markers and lineage-spe-
cifi c markers (negative for CD45, CD3, CD4, CD8, CD11b, 
CD11c, CD19, CD25, Gr1, F4/80 NK1.1, and CD31) and were 
positive for CD105, CD73, and CD44. All MSC populations 
used maintained trilineage differentiation (fat, cartilage, 
and bone) capacity in culture. wtMSC and p53MSC main-
tained similar phenotypes and growth characteristics 
mutation is a gain-of-function mutation (see Supplemental 
Fig. 1; Supplementary materials are available online at 
http://www.liebertonline.com/scd). wtMSC cultured under 
the same conditions, and at the same age, do not have de-
monstrable p53 protein by immunofl uorescence (IF) or by 
western blot analysis, while p53MSC stain heavily by p53 
IF, and have abundant protein by western blot analysis 
[ 13 ]. Freshly isolated MSC and cultured MSC populations 
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 FIG. 1.  Human breast cancer stroma contains nuclear p53. Specifi c anti-p53 IHC of 3 different representative human breast 
cancer specimens containing ( A ) abundant stroma ( B ) moderate amount of stroma, and ( C ) little stroma. Arrows point out 
p53 + nuclei of stromal cells (brown nuclear staining). Frozen tissue was used to colocalize ( D ) anti-α-smooth muscle actin 
(SMA) (green), ( E ) p53 (red, arrows), ( F ) nuclei (blue). ( G ) Merged image shows p53 colocalizing with dapi (purple, arrows) 
within α-SMA + cells. ( H ) Anti-p53 (brown staining) and ( I ) anti-α-SMA (brown staining) immunohistochemistry of con-
secutive sections of non-neoplastic mammary tissue containing mammary epithelial and stromal structures. Boxed areas 
shown in higher power as indicated. The chart summarizes the number of p53 + cells within the epithelial and stromal com-
partments of the human tumors and within benign mammary tissue. 
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wtMSC but, in the absence of infl ammation or a predisposi-
tion to tumors, do not themselves initiate epithelial malig-
nancy (see Supplemental Methods for further details). 
 p53MSC and mammary carcinoma in the Apc Min/+ 
cancer prone mouse 
 To address the effects of stroma on the growth of dormant 
or premalignant mammary cells, we chose a mouse model 
that develops mammary carcinoma at a low but reproducible 
rate. Less than 1% of B6Min mice housed at MIT or UMass 
develop mammary carcinoma as they age (personal obser-
vation). Tumor incidence is directly linked to infl ammatory 
triggers [ 21–23 ] as tumor formation occurs with chronic in-
fection [ 23 ]. Congenital or acquired immunodefi ciency is 
strongly associated with an increased incidence of tumors in 
both human and mice. Immune cells are thought to prevent 
tumor outgrowth by either direct elimination of tumor cells 
or by maintaining an equilibrium state where occult tumors 
are kept in check. These processes are termed immunosur-
veillance and immunoediting [ 24–26 ]. Rag2-defi cient mice 
lacking T, B, and NK-T immune cells are at an increased 
risk for chemically induced tumors attributed to genetic 
with doubling times of 26 and 28 h, respectively. B6 mice 
were infused with 1 million p53MSC or age-matched cul-
tured wtMSC labeled with red fl uorescent protein (RFP) 
as control. Infused cultured wtMSC were not maintained 
at detectable levels long term in host tissue, and were not 
found after 3, 6, 9, or 12 months postinfusion (Supplemental 
Fig. 2; Supplementary materials are available online at 
http://www.liebertonline.com/scd). In contrast to wtMSC, 
p53MSC remained detectable in the blood for many months 
postinfusion and were recovered at all time points tested 
( Fig. 2A and  2B and Supplemental Fig. 2). There were no 
gross or microscopic tumors in any tissue from B6 mice. 
The spleen and the marrow cavity contained a few scattered 
RFP + cells ( Fig. 2D ). To confi rm the presence of p53MSC in 
the bone marrow, we cultured the bone marrow and recov-
ered 35 ± 5 RFP-p53MSC colony-forming units per mouse 
( Fig. 2C ), which we calculated was found to be ~3% of the 
stroma. These MSC lacked specifi c hematopoietic or lineage 
markers (CD3, CD4, CD8, CD11b, CD11c, CD19, CD25, Gr1, 
F4/80, and NK1.1), and retained CD44 positivity and the 
ability to differentiate into bone fat and cartilage, confi rm-
ing they were MSC. Further, these data demonstrate that 
p53-mutated MSC have a survival advantage in vivo over 
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 FIG. 2.  Analysis of red fl uorescent protein (RFP)-p53MSC recovered in the mature wild-type mouse after IV injection. RFP-
labeled p53MSC injected IV into wild-type C57BL/6 mice are identifi ed within the circulation and bone marrow cavity. ( A ) 
Fluorescence-activated cell sorting (FACS) analysis of peripheral blood 9 months after injection of 1 × 10 6 RFP p53MSC. ( B ) 
FACS analysis of peripheral blood 9 months after injection of PBS. Boxed area indicates the number of RFP + cells detected. 
( C ) Bone marrow fl ushed from the right femur of mouse shown in Panel  A was grown in culture and RFP-p53MSC recov-
ered. RFP + cells in culture are seen under the fl uorescent inverted tissue culture microscope. ( D ) RFP-specifi c IHC of the 
marrow cavity of the left femur of the same mouse. Arrows highlight brown-colored positive signal in RFP + cells (DAB 
chromogen and hematoxylin counterstain 10×). 
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were evident. Tumors in B6Min mice had a larger propor-
tion of keratinized glands compared with the tumors in the 
B6MinRag mice. The amount of supporting stroma varied 
from small to moderate amounts within a group, and did 
not differ between groups as a whole; p53MSC did not alter 
the amount of stroma in tumors (B6MinRag spontaneous 
tumor 8.39% stroma vs. B6MinRag+p53MSC 8.41% stroma). 
Neutrophilic infi ltrate was noted in all tumors and ter-
minal ductular (alveolar) differentiation was an occasional 
fi nding. 
 p53MSC-induced mammary tumors are 
transplantable into a second host 
 We next assessed p53MSC-induced tumors for malignant 
characteristics. Cell suspensions were prepared from B6Min 
p53MSC tumors and injected into the mammary fat pad of 
secondary B6Min hosts. Tumors formed by 8 days after injec-
tion in 1/3 B6Min mice (1.6 × 0.9 × 0.8 cm). Hematoxylin and 
eosin (H&E) staining revealed adenosquamous carcinoma 
with interspersed fat and stroma, similar in characteristics to 
the original parent tumor as well as to the histology of spon-
taneous mammary tumors arising in aged B6Min mice ( Fig. 
3E and  3F [transplanted tumor] compared with  Figure 3A and 
 3B [parent tumor]). Marked nuclear atypia was noted within 
disorganized glands ( Fig. 3F ), and a large number of cells 
were proliferative by Ki-67 staining ( Fig. 3G ). Transplanted 
tumors contained 1% p53MSC within the stroma, which 
were Ki-67 − . Recovered tumor from the secondary host con-
tained ~1% RFP-p53MSC within a predominantly p53 − (by 
IHC) stroma. Cells from the secondary tumor grew readily 
in tissue culture, and maintained an epithelial morphology 
in monolayer ( Fig. 3H ). We did not isolate any p53MSC in 
mutations and escape of immune-mediated surveillance [ 21 ] 
and for microbially induced tumors attributed to inability 
to down-regulate host infl ammatory response [ 27 ]. Placing 
the Apc Min/+ mutation on the Rag2 background increases the 
incidence of spontaneous mammary carcinoma to ~10% by 5 
months of age. Tumors are usually solitary. 
 p53MSC are recruited to mammary tissue 
of the B6Min and B6MinRag mouse, surround ducts, 
and dramatically increase tumor incidence 
 We tested our hypothesis that circulating p53MSC con-
tribute to carcinoma progression. One million p53MSC, 
wtMSC, or vehicles were injected via the tail vein into fe-
male B6, B6Min, or B6MinRag mice at 8 weeks of age. Mice 
were followed for an additional 4–6 weeks. Fifty percent of 
the B6Min mice and 80% of the B6MinRag mice that received 
p53MSC developed single mammary tumors ranging from 
0.3 to 2.0 cm in size by 4–6 weeks postinjection ( Table 2 ). In 
marked contrast, B6, B6Min, or B6MinRag mice that received 
either vehicle or wtMSC developed no tumors over 6 weeks 
of observation. 
 p53MSC-associated mammary tumors in the B6Min and 
the B6MinRag mouse had histological features similar to 
spontaneous tumors that are found in the aged (>26-week-
old) B6Min and B6MinRag mice ( Fig. 3A–3D , higher-power 
images of B6MinRag p53MSC tumor in Supplemental Fig. 3; 
Supplementary materials are available online at http://www
.liebertonline.com/scd). In p53MSC recipients, mammary 
adenosquamous carcinoma was characterized by highly 
irregular infi ltrative growth pattern with both keratinized 
and nonkeratinized gland units forming small nests, cords, 
and trabeculae. Cellular atypia and increased proliferation 
 T able 2.  M ammary T umor F requency in M ouse M odels 
Group Mammary tumor incidence
B6 0 ( n = 10)
B6+wtMSC (infused) 0 ( n = 10)
B6+BM+marked wtMSC (transplant) 0 ( n = 10)
B6+p53MSC 0 ( n = 10)
B6Min 0 ( n = 10)
B6Min+T REG 0 ( n = 10)
B6Min+wtMSC (infused) 0 ( n = 10)
B6+BM+marked wtMSC (transplant) 0 ( n = 10)
B6Min+p53MSC 50% ( n = 10)*
B6Min+p53MSC+T REG 0 ( n = 10)
B6Rag 0 ( n = 10)
B6MinRag 0 ( n = 10)
B6MinRag+T REG 0 ( n = 10)
B6MinRag+p53MSC 80% ( n = 10)**
B6MinRag+p53MSC+T REG 0 ( n = 10)
B6MinRag+p53MSC+anti-TNF-α 0 ( n = 10)
B6MinRag+p53MSC+isotype control IgG 80% ( n = 10)**
 Mice 6–8 weeks of age at the start. Tumor frequency determined up to 6 
weeks. Several mice removed from study at 4 weeks due to large tumor size. All 
groups with 0 tumor frequency observed for at least 6 weeks. * P = 0.0325, ** P = 
0.0007. 
 Tumor incidence between the C57BL/6Apc Min+/− (B6Min)+MSC and 
C57BL/6Apc Min+/− /Rag2 − / − (B6MinRag)+MSC groups was not statistically 
signifi cant;  P = 0.35. 
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surrounded by a small population of RFP-p53MSC. We con-
fi rmed p53 nuclear expression (indicative of mutant protein 
expression) within a subset of the stromal cells by anti-p53 IF 
staining, consistent with continued in vivo expression of the 
mutant protein ( Fig. 4E ). The majority of stromal cells within 
the tumor were RFP − , and therefore of host origin ( Fig. 4C 
and  4D and  Supplemental Table 1 ). This pattern closely re-
sembled the fi ndings in our human samples, where p53 + 
stromal cells comprised 1%–5% of the tumor stroma, while 
95%–99% of the cells failed to stain for p53. 
 Peripheral blood of the B6Min and B6MinRag mice that 
had developed mammary carcinoma contained <1% cir-
culating RFP-expressing p53MSC-derived cells, similar to 
wt mice. The spleen contained between 1% and 5% RFP-
expressing cells. The p53MSC in the spleen maintained CD44 
expression, while lacking surface markers of differentiation: 
CD45, CD3, CD4, CD8, CD11b, CD11c, CD19, CD25, Gr1, F4/80, 
CD31, and NK1.1 by FACS analysis. Bone marrow contained 
few RFP-p53MSC. The p53MSC recovered from B6min or 
B6MinRag mice with tumors had the same distribution and 
culture; however, the quantity of tissue for this purpose was 
limited. 
 p53MSC home to at-risk mammary epithelium 
 p53MSC were detected in the mammary tissue of mice fol-
lowing injection with RFP-labeled p53MSC, but the level of 
engraftment differed substantially between recipient mouse 
strains. B6 mice had rare single MSC juxtaposed to mam-
mary ducts ( Supplemental Table 1 ). B6Min (data not shown) 
and B6MinRag mice had foci of abundant p53MSC-derived 
cells surrounding several ducts ( Fig. 4A and  4B ), while other 
ducts within the same mouse had few to no detectable RFP-
p53MSC (summarized in  Supplemental Table 1 ) even in the 
absence of tumors. This patchy engraftment was consistent 
between B6Min and B6MinRag mice. In areas of tumor, 
p53MSC were identifi ed both at the periphery of tumors, 
and within the infi ltrating stroma, and accounted for 1%–5% 
of cells within tumors ( Fig. 4C and  4D and  Supplemental 
Table 1 ). Carcinomas were consistently infi ltrated with, and 
B6Min
Spontaneous
Mammary Tumor
Adenosquamous Mammary Carcinoma Transplanted into
a B6Min Recipient.
p53MSC Induced
Mammary Carcinoma
B6MinRag
BA
DC
FE
HG
 FIG. 3.  p53MSC induce mammary adenosquamous carci-
noma in the B6Min and B6MinRag mouse. Comparison of 
histology of spontaneous mammary carcinoma and p53MSC-
induced mammary tumor in the mouse model. Tumor tissue 
from aged (>26-week-old) untreated B6Min and B6MinRag 
mice from previously published studies was used for com-
parison purposes, as no spontaneous tumors arose during 
our study period. Tumors from ( A ) aged B6Min, ( B ) 8-week-
old B6Min injected with p53MSC and evaluated 4–6 weeks 
later, ( C ) aged B6MinRag, ( D ) 8-week-old B6MinRag injected 
with p53MSC and evaluated 4–6 weeks later demonstrate 
striking similarities when compared with each other in-
cluding highly irregular infi ltrative growth pattern with 
nonkeratinized and keratinized glands arranged in variable 
sized nests and cords, cellular atypia, and nuclear pleomor-
phism of neoplastic cells. p53MSC-induced mammary tumor 
(such as the one shown in Panel  B ) was transplanted as a cell 
suspension into the mammary fat pad of secondary recip-
ient B6Min mice. ( E ) Low-power and ( F ) high-power images 
of transplanted tumor reveal suspended tumor cells have 
been organized into abnormal neoplastic glands. Increased 
mitotic fi gures, including 2 abnormal ones (arrows) typify 
active neoplastic cell proliferation. ( G ) Ki-67-specifi c immu-
nostaining of transplanted mammary carcinoma highlights 
increased proliferative activity consistent with neoplasia. ( H ) 
Cells from the tumor shown in  E and  F grow readily in tissue 
culture as an epithelial monolayer. 40× inverted microscope 
image. Images ( A–F ), hematoxylin and eosin staining. ( G ), 
Ki-67 IHC, hematoxylin counter stain. Original magnifi cation 
( A–E ,  G ) 10×, ( E ) 20×, ( F ,  H ) 40×. 
 HOUGHTON ET AL. 1160
tumors, and behaved as previously described for primary 
p53MSC. These cells lacked the surface markers: CD45, CD3, 
CD4, CD8, CD11b, CD11c, CD19, CD25, Gr1, F4/80, CD31, and 
behavior (when placed in culture or injected back into the 
wt mouse) as those isolated from wt nontumor-bearing mice. 
Specifi cally, reinjected p53MSC into B6 mice did not form 
A
F
D
B C
E
Ki67 Staining of Mammary Ductal Epithelium of B6MlnRag Mice
Group
Tumor
Incidence
Ki67
Staining
Index
40
P < 0.05
P < 0.001
30
20
10
0
B6MinRag
Untreated
K
i-6
7 
La
be
lin
g 
In
de
x
(%
 K
i-6
7 
P
os
iti
ve
 C
el
ls
)
B6MinRag + MSC
Isotype Control IgG
B6MinRag + MSC
Anti-TNF IgG
7.78 ± 1.46 17.3 ± 3.24 3.00 ± 0.55
0/10 8/10 0/10
No Treatment MSC +
Isotype Control lgG
MSC +
Anti-TNF lgG
*
*
 FIG. 4.  p53MSC in mammary epithe-
lium of the B6MinRag increase mam-
mary duct epithelium proliferation via 
tumor necrosis factor (TNF) signaling. 
( A ) 10× and ( B ) 40× (boxed image 
from ( A ) red fl uorescent protein (RFP)-
immunohistochemistry (IHC) (brown 
cytoplasmic staining) showing clusters 
of p53MSC closely opposed to mam-
mary duct epithelium. ( C ) Direct fl uo-
rescence imaging of tissue surrounding 
mammary carcinoma. Abundant RFP + 
(top image black and white fl uores-
cent image, below; pseudocolored 
image). Asterisk denotes a duct em-
bedded within RFP + stroma. ( D ) RFP − 
IHC reveals RFP + MSC at the edge of 
mammary tumor and within stroma 
(arrows). ( E ) p53 IF staining (green) of 
stroma surrounding mammary car-
cinoma. Green nuclei of p53 + stromal 
cells are highlighted by arrows. ( F ) 
Ki-67-specifi c IHC of mammary epi-
thelium of B6MinRag mouse receiving 
no intervention (no treatment—fi rst 
image), p53MSC and isotype control 
IgG (second image), or p53MSC plus 
anti-TNF-α IgG (third image). Ki-67 
staining is confi ned to epithelial cells. 
The stromal cells were predominantly 
nonproliferative. We did not detect any 
Ki-67 staining in p53MSC. Tumor inci-
dence and Ki-67 proliferation index is 
shown below histology as a chart form 
and as a bow-and-whisker plot for Ki-67 
staining. 
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tissue ( Supplemental Table 1 ) verifying that the anti-TNF-α 
treatment did not affect p53MSC viability or engraftment 
ability, but dramatically impacted the ability of p53MSC to 
induce tumor in at-risk tissue similar to our fi ndings with 
T REG infusion. 
 Proliferation of malignant cells in at-risk tissue 
 p53MSC are detected juxtaposed to normal duct epi-
thelium in the B6Min and B6MinRag mice, and rarely in 
mammary tissue of B6 mice that do not develop mam-
mary carcinoma. We examined Ki-67 expression in these 
nonmalignant mammary tissues to gauge the level of cell 
proliferation within the ductal epithelium prior to onset of 
overt neoplasia. Baseline proliferation of mammary ductal 
cells in both the B6Min (data not shown) and B6MinRag 
( Fig. 4E and  4F ) mice were higher than control B6 mice 
(data not shown). Proliferation within the B6MinRag tis-
sue increased dramatically with the addition of p53MSC, 
and was unaffected by the addition of control Ig Ab treat-
ment ( Fig. 4E and  4F ). Addition of T REG cells or anti-TNF-α 
antibody to B6Min (data not shown) and B6MinRag mice 
( Fig. 4E and  4F ) with p53MSC decreased the proliferation 
rate below baseline levels for these strains to proliferative 
levels that were indistinguishable from levels found in 
wt non-Min mice. These data indicated that at baseline, 
at-risk mammary epithelium in Min mice had a higher 
proliferation rate, which was dramatically augmented 
by p53MSC. Anti-TNF-α therapy prevented the p53MSC-
mediated increase in proliferation, and restored epithelial 
proliferation rates to levels found in normal risk non-Min 
individuals. 
 p53MSC increased proliferation and migration 
of human breast carcinoma cells in vitro and in vivo 
 To tease out the mechanisms involved in immune reg-
ulation of mammary carcinoma, and establish relevance to 
human disease, we utilized a combination of in vitro cell cul-
ture systems and human breast cancer xenograph models. 
We fi rst evaluated the effects of soluble factors produced by 
p53MSC on the MCF-7 breast cancer cell line. p53MSC had a 
phenotype consistent with the one that is reported for CAF. 
p53MSC expressed higher levels of MMP3, MMP9, fgf1, and 
VEGF [ 13 ] and secreted high levels of MCP-1 and RANTES 
when compared with wtMSC and had low but detectable 
levels of IL-6, TNF-α, and IFN-γ ( Supplemental Table 2 ; 
Supplementary materials are available online at http://www 
.liebertonline.com/scd) . Conditioned cell-free media from 
24-h p53MSC cultures (but not wtMSC cultures) increased 
proliferation of the MCF-7 human breast cancer cell line in 
a consistent and sustained fashion ( Fig. 5A ) and increased 
the mobility of MCF-7 cells in a wound-healing assay ( Fig. 
5B ). Direct addition of TNF-α to MCF-7 wounded monolay-
ers did not signifi cantly increase the motility of the breast 
cancer cells (data not shown). In contrast, p53MSC cell-free 
conditioned media by itself (which contain on average 153 
pg/mL of secreted TNF-α) stimulated motility and migra-
tion of MCF-7 cells signifi cantly over control conditions 
( Fig. 5C ). The addition of exogenous TNF-α to p53MSC 
cultures prior to harvesting media increased motility fur-
ther, allowing 60% healing by 24 h, and complete healing 
by 48 h. Adding neutralizing anti-TNF-α during p53MSC 
culture resulted in conditioned media that did not support 
NK1.1, retained CD44 positivity, and retained the ability to 
differentiate into bone fat and cartilage, confi rming they 
were MSC. Further, these data suggest that our results do not 
refl ect phagocytosis of p53MSC by macrophages. These data 
also suggest that the p53MSC did not gain in vivo growth 
characteristics as a result of passage through the mouse. 
The phenotype of p53MSC recovered from B6, B6Min, and 
B6MinRag was similar with regard to the number in circula-
tion, the number recovered from the marrow cavity (~3% of 
the stromal cells of the marrow), and surface marker expres-
sion. Thus these results support our hypothesis that tissue 
environment of at-risk tissue itself orchestrates engraftment, 
proliferation, and proneoplastic effects of p53MSC in the 
cancer prone model, but that outside of the local environ-
ment of the tumor, p53MSC behave normally. 
 Wild-type CD25 + regulatory T cells abolish p53MSC 
augmentation of tumor formation in B6Min 
and B6MinRag mice 
 CD4 + CD25 + regulatory (T REG ) cells signifi cantly con-
tribute to immune homeostasis in autoimmune diseases 
[ 27 ], chronic infl ammatory diseases [ 29 ], and cancer 
[ 27 , 30 , 31 ] through down-regulation of destructive infl am-
matory responses arising from CD4 + T cells as well as cells 
of innate immunity. In our present system, infusion of wt 
T REG cells completely inhibited the cancer phenotype. While 
50% of the B6Min and 80% of the B6MinRag mice injected 
with p53MSC developed clinically relevant mammary car-
cinoma, none of the B6Min or B6MinRag mice injected with 
T REG cells along with the p53MSC developed mammary 
tumors ( Table 2 ). This fi nding was not the result of T REG elim-
ination of p53MSC, as we were able to identify p53MSC in 
the peripheral blood and bone marrow of these mice. The 
pattern, number, and distribution of p53MSC in the blood 
and marrow were similar between mice receiving T REG and 
vehicle. Examination of the mammary tissue of T REG recipi-
ents revealed several important differences compared with 
controls. Few, single p53MSC were found in the mammary 
epithelium of B6MinRag mice receiving p53MSC and T REG 
( Supplemental Table 1 ). These cells were juxtaposed to mam-
mary epithelium suggesting that, in the presence of T REG 
cells, p53MSC remain viable and retain their ability to home 
to the mammary tissue at risk. However, despite their local-
ization to mammary tissue, no tumor formed with T REG cells 
present. Thus, immune dysregulation appears to be required 
for p53MSC-orchestrated tumor initiation and growth in the 
mammary epithelium. 
 p53MSC-induced mammary tumor formation in 
B6Min and B6MinRag mice was TNF-α-dependent 
 Previous studies from our group show that intestinal and 
mammary tumor development in Apc Min/+ mice depends 
upon overexpression of TNF-α [ 22 , 23 , 32 ]. In these models, 
T REG cells modulate the immune response, in part by re-
storing elevated TNF-α levels to normal. In our present 
study, anti TNF-α, but not isotype control Ig, effectively pre-
vented tumor formation in both the B6Min and B6MinRag 
mice receiving p53MSC, indicating that p53MSC modulated 
cancer via a TNF-α-dependent signaling pathway ( Table 
2 ). Anti-TNF-α therapy did not alter peripheral circulating 
levels of p53MSC and p53MSC were present in mammary 
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responsible for increased motility of breast cancer cells. The 
effect of TNF-α is on MSC themselves rather than a direct 
effect of TNF-α on the breast cancer cells. 
 Next we assessed the interaction between p53MSC and 
MCF-7 cells in vivo. NOD-SCID mice received 1 million 
MCF-7 cell wound healing ( Fig. 5C ). However, neutralizing 
the TNF-α in the conditioned media just prior to adding it 
to the MCF-7 monolayers did not have a signifi cant effect 
on healing kinetics. These data suggest that TNF-α stimu-
lates the p53MSC in an autocrine manner to secrete factors 
 FIG. 5.  Factors elaborated by p53-mutated mesenchymal stem cells (MSC) increase growth and motility of human breast 
cancer in vitro and allow homing to breast cancer in vivo. ( A ) Human breast cancer cell line MCF-7 was grown in control 
media or cell-free p53MSC-conditioned media. Cell counts were determined at the indicated times. ( B ) Confl uent MCF-7 
wounded monolayers were grown in MCF-7 media (open circle) or p53MSC-conditioned media (black circle) for 48 h and 
the wound remaining measured and recorded as a percent of the original wound. ( C ) MCF-7-wounded monolayers were 
grown in media as indicated and percent wound closure recorded at 24 h. Cell counts and wound-healing experiments 
were performed using triplicate plates, repeated a minimum of one additional time, and reported as the mean ± 1 SD. For 
A–C; * P < 0.05 unless otherwise noted. ( D ) Red fl uorescent protein (RFP)-p53MSC surround GFP-labeled MCF-7 cells in the 
NOD-SCID mouse. ( E ) wtMSC labeled with RFP do not migrate toward GFP-labeled MCF-7 cells. ( F ) Cartoon depicting the 
distribution of p53MSC within human breast cancer stroma and within surrounding muscle. 
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of the stroma, or vice versa, that is, if the stroma forces a 
neoplastic phenotype on the epithelial cell, thus creating 
the classical chicken and egg dilemma. Our studies using 
p53MSC and wtMSC in the Apc Min+/− mouse demonstrate 
that stromal cell mutations accelerate tumor progression 
in at-risk tissue. 
 For the most part, it has been assumed that transformed 
cells within an organ proliferate and orchestrate stroma 
recruitment and organization via infl uence on local fi bro-
blasts [ 35–37 ], or through epithelial–mesenchymal transi-
tion of normal or transformed epithelial cells [ 38 ] or by 
recruiting bone marrow-derived mesenchymal [ 39–41 ] and 
other progenitor cells [ 42 ]. Factors elaborated by stromal 
cells create a unique milieu that has profound effects on 
cancer cell proliferation, invasion, and migration [ 43–45 ] 
similar to the contribution of activated stromal cells to 
wound healing. This viewpoint of stromal cell–cancer 
cell interaction presupposes that the tumor cells orches-
trate the complex interaction with the stromal cells, and 
these stromal cells likely undergo gene mutations as a re-
sult of the hyperproliferative environment of the tumor. 
This view maintains the stromal cells are under the in-
fl uence and direction of the cancer cell. Our data support 
an alternate view that stromal cells may initiate epithelial 
transformation via cytokine-mediated signaling of at-risk 
tissue and cause the transition of preneoplastic tumor 
foci to overt malignant tumors by promoting tumor cell 
proliferation. 
 Though controversial, there are data suggesting that 
p53 mutations can be found selectively within the stromal 
component of breast cancer and may be associated with a 
more aggressive phenotype [ 14 , 15 , 17–19 ]. The vast majority 
(95%–99%) of stromal cells within the B6Min+p53MSC 
and B6MinRag+p53MSC mammary tumors were host-
derived, and thus wt for p53. Although rare, p53MSC 
were found both within tumors, and at the very edge of 
the epithelial cancer cells interface. Thus, sampling at any 
distance from the tumor itself would lead to a negative re-
sult for mutant p53, and sampling within the tumor could 
yield negative results due to sampling error based on the 
p53MSC being a small minority of cells within the stroma. 
Immunohistochemistry and IF analysis of our archived 
human breast cancer samples verifi es that in 67% of cases 
examined, overexpression of p53 was found suggesting a 
mutant protein, but p53 + stromal CAF were only 1%–5% of 
the total stromal cells. Thus, p53CAF are <5% of the total 
stroma, but may have a major impact on the biology of the 
tumor. 
 Despite this controversy, our human data and compel-
ling data from other systems warrants investigation of the 
association between p53MSC and breast cancer. MCF-7 
mammary carcinoma cells grow faster and demonstrate 
a more aggressive phenotype when mixed with p53-defi -
cient fi broblasts compared with wt fi broblasts suggesting 
a nonautonomous mechanism of p53-mutated stroma and 
transformed mammary epithelial cells [ 11 ]. In these stud-
ies, p53-defi cient fi broblasts are derived from p53 null mice. 
Signaling differs between p53-deleted animal models and 
clinically relevant p53 point mutations that occur in human 
disease. Our model addresses the function of clinically rel-
evant p53 mutations [ 20 ] in mesenchymal cells and their 
ability to initiate cancer in a tissue-specifi c fashion in an 
at-risk mammary carcinoma model. Our results in both 
p53MSC, or wtMSC as a single intracapsular injection, fol-
lowed 1 week later by 1 × 10 6 GFP-labeled MCF-7 cells or 
mouse embryonic fi broblast (MEF) cells injected onto the 
fl ank. At 4 weeks, p53MSC were detected in the surround-
ing skin and muscle and encasing small well-demarcated 
GFP-MCF-7 tumors ( Fig. 5D , and cartoon in  Fig. 5F ). p53MSC 
did not migrate to normal fl ank nor to normal mammary 
fat pads, or in response to the primary GFP-MEF cell cul-
ture (data not shown). In contrast to p53MSC, wtMSC could 
not be recovered in MCF-7 tumors or peripheral tissues in-
cluding mammary fat at times up to 4 weeks ( Fig. 5E ). These 
fi ndings confi rm that p53MSC migrate toward human breast 
cancer cells, providing relevance to human disease. 
 Discussion 
 Adults have in situ malignancy in multiple organs by 
midlife [ 1–4 ], but remarkably few people manifest clinical 
disease. We sought to understand factors involved in allow-
ing subclinical cancers to progress to overt clinical disease. 
We chose our Apc Min+/− mouse model because of the low in-
cidence of mammary tumors in a controlled environment, 
and the association of clinically apparent tumor formation 
with increasing systemic infl ammation. This pattern follows 
the known association of chronic infl ammation with many 
types of human tumors. Apc mutations can also be found 
in human breast cancer [ 33 ] and breast cancer cell lines [ 34 ]. 
Thus the Apc Min+/− mouse represents a model whereby the 
mammary tissue is at-risk for malignancy, but depending 
upon the local environment, cancer potential may or may 
not be realized. 
 Our experiments show that genetic changes including 
p53 mutations in MSC are well-tolerated in genetically 
normal tissues, and are not associated with an increase in 
cancer incidence and that p53MSC have a homing advan-
tage over wtMSC to “at-risk” peripheral tissue by an as of yet 
unclear mechanism. Alone, p53MSC are unable to induce 
disease; however, in combination with systemic immune 
dysregulation, they allow neoplastic growth in at-risk mam-
mary tissue. Restoration of immune homeostasis prevents 
disease despite unchanged genetic mutations within both 
the stromal and epithelial compartments strongly support-
ing the notion that immune modulation may be an effective 
means to prevent cancer in high-risk individuals. 
 Epigenetic and genetic changes within tumors, which 
drive proliferation and aggressive clinical behavior, have 
historically been assessed at the level of the cancer cell it-
self, with less attention given to gene alterations within 
the supporting stroma. Animal models of cancer typically 
focus on gene mutations within the epithelial cell com-
partment, and in many cases multiple gene alterations 
are required to initiate tumors. The behavior of resulting 
tumors differs from those found in human and rarely is 
the spectrum of disease caused by epithelial mutations 
alone as diverse as the diseases seen in humans. One way 
to view these discrepancies is to recognize that genes 
targeted to specifi c cell populations alter the behavior of 
“tumor” cells, but do not take into account the contribu-
tion of stromal cells. Several recent reports demonstrate 
the importance of mutations within tumor stroma and the 
dramatic infl uence these cells have on the behavior of the 
tumor as a whole [ 8 , 14 , 15 ]. It is not clear, however, if the 
neoplastic epithelial cells infl uence and dictate behavior 
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that new targets for preventative therapy for at-risk human 
populations can be developed. One can also envision the 
possibility that quiescent metastatic foci, which may be-
come active many years after seemingly curative cancer 
therapy, could be kept in check by therapy targeted at dis-
rupting infl ammation–stroma–cancer cell interactions. 
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